Barry James Maurer

US Patent:

6368831, Apr 9, 2002

Filed:

Dec 23, 1999

Appl. No.:

09/471944

Inventors:

Barry J. Maurer - Sunland CA
C. Patrick Reynolds - Sherman Oaks CA

Assignee:

Childrens Hospital Los Angeles - Los Angeles CA

International Classification:

C12N 1509

US Classification:

435 692, 435 15, 435 721, 435 71, 435 723, 435 4, 435193, 435110, 514 2, 514 28, 514 25, 514 54, 5142378, 514613, 514617, 514 1, 536 5, 536 245

Abstract:

A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degredation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors and/or 1-acylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine.

US Patent:

7169819, Jan 30, 2007

Filed:

Dec 5, 2001

Appl. No.:

10/010914

Inventors:

Shanker Gupta - Rockville MD, US
Barry J. Maurer - Sylmar CA, US
C. Patrick Reynolds - Sherman Oaks CA, US
B. Rao Vishnuvajjala - Rockville MD, US

Assignee:

Childrens Hospital Los Angeles - Los Angeles CA

International Classification:

A61K 31/07
A61K 47/00
A61P 35/00

US Classification:

514725, 514728, 514729, 514731, 514739, 514772, 514783, 514937, 514938, 514975

Abstract:

A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.

US Patent:

7476692, Jan 13, 2009

Filed:

Feb 19, 2004

Appl. No.:

10/782459

Inventors:

Shanker Gupta - Rockville MD, US
C. Patrick Reynolds - Sherman Oaks CA, US
Barry J. Maurer - Sylmar CA, US
B. Rao Vishnuvajjala - Rockville MD, US

Assignee:

Childrens Hospital Los Angeles - Los Angeles CA

International Classification:

A61K 31/19
A61K 31/13

US Classification:

514557, 514667

Abstract:

The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0. 1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0. 2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.

US Patent:

7780978, Aug 24, 2010

Filed:

Jun 29, 2005

Appl. No.:

11/170561

Inventors:

Barry J. Maurer - Sylmar CA, US
Charles Patrick Reynolds - Sherman Oaks CA, US
David W. Yesair - Byfield MA, US
Robert Travis McKee - Jacksonville FL, US
Stephen W. Burgess - Chelsea AL, US
Walter A. Shaw - Birmingham AL, US

Assignee:

Childrens Hospital Los Angeles - Los Angeles CA

International Classification:

A61K 47/00
A61K 31/16
A23L 1/308

US Classification:

424439, 514613, 426 72

Abstract:

The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

US Patent:

7785621, Aug 31, 2010

Filed:

Jan 30, 2004

Appl. No.:

10/767352

Inventors:

Barry J. Maurer - Sylmar CA, US
Charles Patrick Reynolds - Sherman Oaks CA, US
David W. Yesair - Byfield MA, US
Robert Travis McKee - Jacksonville FL, US
Stephen W. Burgess - Chelsea AL, US
Walter A. Shaw - Birmingham AL, US

Assignee:

Childrens Hospital Los Angeles - Los Angeles CA

International Classification:

A61K 47/00
A61K 31/16
A23L 1/308

US Classification:

424439, 514613, 426 72

Abstract:

The present invention provides an edible composition for oral delivery of an active agent such as a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

US Patent:

20050101674, May 12, 2005

Filed:

Nov 12, 2003

Appl. No.:

10/712763

Inventors:

Barry Maurer - Sylmar CA, US
Charles Reynolds - Sherman Oaks CA, US

International Classification:

A61K031/16
A61K031/225

US Classification:

514625000

Abstract:

The present invention relates to a method of treating a hyperproliferative disorder comprising administering a ceramide generating retinoid comprising a retinoic acid derivative or a pharmaceutically acceptable salt thereof, and D-threo-PPMP as a ceramide degradation inhibitor or a pharmaceutically acceptable salt thereof, wherein the hyperproliferative disorder is a tumor; and wherein the ceramide generating retinoid is administered in an amount effective to produce necrosis, apoptosis or both in the tumor, and the ceramide degradation inhibitor is administered in an amount effective to increase the necrosis, apoptosis or both in the tumor over that expected to be produced by the sum of that produced by the ceramide generating retinoid and the ceramide degradation inhibitor when administered separately.

US Patent:

20050271707, Dec 8, 2005

Filed:

Jun 29, 2005

Appl. No.:

11/170371

Inventors:

Barry J. Maurer - Sylmar CA, US
Charles Patrick Reynolds - Sherman Oaks CA, US
David W. Yesair - Byfield MA, US
Robert Travis McKee - Jacksonville FL, US
Stephen W. Burgess - Chelsea AL, US
Walter A. Shaw - Birmingham AL, US

International Classification:

A61K047/00
A61K031/337

US Classification:

424439000, 514449000

Abstract:

The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

US Patent:

20100035911, Feb 11, 2010

Filed:

May 16, 2007

Appl. No.:

12/301089

Inventors:

Barry James Maurer - Idalou TX, US
C. Patrick Reynolds - Lubbock TX, US

International Classification:

A61K 31/167
A61K 31/4745
A61K 31/337
A61P 35/00
A61K 31/44

US Classification:

514283, 514613, 514449, 514353

Abstract:

A method of treating a hyperproliferative disorder, including a cancer, in a subject in need of such treatment, comprising administering to said subject a pharmaceutical combination containing a treatment effective amount of: (a) a vitamin A derivative (i.e., a retinoid), or a pharmaceutically acceptable salt thereof, and an inhibitor of microtubule structure or function; or (b) a combination containing fenretinide (i.e., N-(4-hydrophenyl) retinamide, 4-HPR) and ABT-751 (i.e., N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide). Vitamin A derivatives that may be useful for this invention according to (a) include, but are not limited to, all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide. Microtubule inhibitors that may be useful for this invention according to (a) include, but are not limited to, inhibitors of the Vinca binding domain (e.g., vincristine, vinblastine, vinorelbine, and cryptophycin 52), inhibitors of the Taxane domain (e.g., paclitaxel, docetaxel, and epothilones), and inhibitors of the colchicine site (e.g., colchicine, ABT-751, CI-980, and combretastatin). A preferred retinoid according to (a) is fenretinide. A preferred microtubule inhibitor according to (b) is ABT-751.